Abstract
Nivolumab or pembrolizumab is the standard second-line treatment for patients (pts) with advanced NSCLC. Anlotinib is an oral VEGFR, FGFR, PDGFR and c-Kit tyrosine kinase inhibitor. The interaction between tumor immune microenvironment and angiogenesis has been well established. This study was designed to assess the benefit and optimal time of nivolumab or pembrolizumab plus anlotinib in previously treated advanced NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have